Skip to main content
. 2020 Nov 23;7(1):FSO655. doi: 10.2144/fsoa-2020-0129

Table 3. . Treatment of toxicity in the patient population.

ICIs Patients with steroids (n) Patients with hormone (n) Patients with biologic therapy (n)
Atezolizumab 2 - -
Avelumab 1    
Durvalumab - 1  
Ipilimumab 10 9  
Nivolumab 21 17 2
Pembrolizumab 12 7 3
Combination 4 4 1
Total (%) Steroids 53% Hormone 40% Biologic 7%

ICI: Immune checkpoint inhibitor.